CVS Health Clears Low Earnings Bar, Leads S&P 500 On Return To Growth In '25

CVS Health Corporation (CVS), a leading healthcare solutions provider, has reported strong fourth-quarter earnings, beating analysts' expectations and signaling a return to growth in 2025. The company's adjusted earnings per share (EPS) of $1.19 and revenue of $97.71 billion surpassed Wall Street's estimates, reflecting the company's continued growth in key areas of its business. CVS Health's stock price surged by over 14% in the morning following the positive report, reversing a 28% decline over the past 12 months.

CVS Health's turnaround plan, led by new CEO David Joyner, is focused on addressing industry-wide challenges and strengthening the company's Aetna business. The company is implementing a multiyear process that includes cost cuts of approximately $2 billion over the next several years. This plan aims to improve the profitability of the Health Benefits segment and drive growth in other areas of the business.

The company's Pharmacy and Consumer Wellness segment contributed significantly to the growth, with sales increasing by more than 7% year-over-year. This growth was driven by higher prescription volume, a favorable pharmacy drug mix, and increased contributions from healthcare delivery assets. CVS Health's pharmacy and consumer wellness division booked $33.51 billion in sales for the fourth quarter, up more than 7% from the same period a year earlier.

CVS Health's 2025 adjusted EPS guidance of $5.75 to $6.00 is in line with Wall Street's expectations and reflects the company's optimism about its growth prospects. Jefferies Healthcare Services equity research analyst Brian Tanquilut joins Morning Brief to discuss the company's growth prospects following its optimistic outlook. Tanquilut explains that the company's earnings call provided a clear path for the company to exceed expectations in upcoming quarters, following previous periods of weaker performance. The company's 2025 profit guidance is driving investor optimism, as it indicates significant upside potential over the next few years.

However, Tanquilut cautions that this turnaround strategy remains a multiyear process, as the company works to strengthen its Aetna business and pricing power. CVS Health's success in the long term will depend on its ability to innovate and adapt to changing market conditions, as well as the success of its turnaround plan.



In conclusion, CVS Health's strong fourth-quarter earnings and optimistic outlook for 2025 signal a return to growth for the company. The company's turnaround plan, focused on addressing industry-wide challenges and strengthening its Aetna business, is driving investor optimism. The Pharmacy and Consumer Wellness segment's growth, driven by higher prescription volume and a favorable pharmacy drug mix, contributed significantly to the company's success. While the turnaround strategy remains a multiyear process, CVS Health's ability to innovate and adapt to changing market conditions will be crucial for its long-term success.